Skip to main content
SpringerLink
Log in

Lobectomy After Induction Therapy for NSCLC in the Presence of Persistent N2 Disease

  • Chapter
  • First Online:
Difficult Decisions in Thoracic Surgery

Part of the book series: Difficult Decisions in Surgery: An Evidence-Based Approach ((DDSURGERY,volume 1))

  • 1327 Accesses

Abstract

Patients who undergo induction therapy for N2 NSCLC should have histologically documented N2 disease and should be restaged following induction therapy to determine the post-induction status of the mediastinal lymph nodes. Patients who have demonstrable disease need to be stratified to determine if the nodal disease is single station, non-bulky, and macroscopic versus microscopic to determine their potential for cure. Invasive restaging has limited sensitivity and negative predictive indices. Patients with limited single station disease and patients with negative restaging are likely to benefit from surgery. Patients requiring a pneumonectomy should not be offered resection.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Veermachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.

    Article  Google Scholar 

  2. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent Cisplatin/Etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:18880–92.

    Google Scholar 

  3. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 1996;111:123–31.

    Article  CAS  PubMed  Google Scholar 

  4. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Mentzer SJ, Sugarbaker DJ. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000;70:1826–31.

    Article  CAS  PubMed  Google Scholar 

  5. Betticher DC, Schmitz SH, Totsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance after Docetaxel-Cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer; a multicenter phase II trial. J Clin Oncol. 2003;21:1752–9.

    Article  CAS  PubMed  Google Scholar 

  6. Steger V, Walles T, Kosan B, Walker T, Kyriss T, Veit S, et al. Trimodal therapy for histologically proven N2/3 non-small cell lung cancer: mid-term results and indicators for survival. Ann Thorac Surg. 2009;87:1676–83.

    Article  PubMed  Google Scholar 

  7. Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.

    Article  PubMed  Google Scholar 

  8. Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomized controlled trial. Lancet. 2009;374:379–86.

    Article  CAS  PubMed  Google Scholar 

  9. Stephani A, Alifano M, Bobbio A, Grigoriou M, Jouni R, Magdeleinat P, et al. Which patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-yer experience in 175 patients. J Thorac Cardiovasc Surg. 2010;140:356–63.

    Article  Google Scholar 

  10. Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, Phannenberg C, et al. Phase II trial of a trimodality regimen for stage III non-small cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with Carboplatin and Paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol. 2010;28:942–8.

    Article  CAS  PubMed  Google Scholar 

  11. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, Altorki NK. Survival of patients with stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011;141:48–55.

    Article  PubMed  Google Scholar 

  12. Meacci E, Cesario A, Cusumano G, Lococo F, D’Angelillo R, Dall’Armi V, et al. Surgery for patients with persistent pathological N2 IIIA stage in non-small cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. Eur J Cardiothorac Surg. 2011;40:656–63.

    PubMed  Google Scholar 

  13. Shitani Y, Funakoshi Y, Inoue M, Takeuchi Y, Okumura M, Maeda H, et al. Pathological status of mediastinal lymph nodes after preoperative concurrent chemoradiotherapy determines prognosis in patients with non-small cell lung cancer. Ann Thorac Cardiovasc Surg. 2012;18:530–5.

    Article  Google Scholar 

  14. Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, et al. Radiation Therapy Oncology Group protocol 0229: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 2012;84:456–63.

    Article  PubMed  Google Scholar 

  15. Cerfolio RJ, Maniscalco L, Bryant AS. The treatment of patients with stage IIIA non-small cell lung cancer from N@ disease: who returns to the surgical arena and who survives. Ann Thorac Surg. 2008;86:912–20.

    Article  PubMed  Google Scholar 

  16. Takeda S, Maeda H, Okada T, Ymaguchi T, Nakagawa M, Yokota S, et al. Results of pulmonary resection following neoadjuvant therapy for locally advanced (IIIA–IIIB) lung cancer. Eur J Cardiothorac Surg. 2006;30:184–9.

    Article  PubMed  Google Scholar 

  17. Cerfolio RJ, Bryanbt AS, Spencer SA, Bartolucci AA. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg. 2006;80:1224–30.

    Article  Google Scholar 

  18. Kim AW, Liptay MJ, Bonomi P, Warren WH, Basu S, Farlow EC, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011;92:233–43.

    Article  PubMed  Google Scholar 

  19. Doddoli C, Barlesi F, Trousse D, Robitail S, Yena S, Astoul P, et al. One hundred consecutive pneumoectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg. 2005;130:416–25.

    Article  PubMed  Google Scholar 

  20. Rebollo-Aguirre A, Ramos-Font C, Portero RV, Cook GJR, Elvira JML, Tabares AR. Is FDG-PET suitable for evaluating neoadjuvant therapy in non-small cell lung cancer? Evidence with systematic review of the literature. J Surg Oncol. 2010;101:486–94.

    PubMed  Google Scholar 

  21. Jaklitch MT, Gu L, Demmy T, Harpole DH, D’Amico TA, McKenna RJ, et al. Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALBG Protocol 39803. J Thorac Cardiovasc Surg. 2013;146:9–16.

    Article  Google Scholar 

  22. Marra A, Hillejan L, Fechner S, Stamatis G. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg. 2008;135:843–9.

    Article  PubMed  Google Scholar 

  23. Szlubowski A, Herth FJF, Soja J, Kolodziej M, Figura J, Cmiel A, et al. Endobronchial ultrasound-guided needle aspiration in non-small-cell lung cancer restaging verified by transcervical bilateral extended mediastinal lymphadenectomy – a prospective study. Eur J Cardiothorac Surg. 2010;37:1180–4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Boston Medical Center, Boston University School of Medicine, B-402, 88 East Newton Street, Boston, MA, 02118, USA

    Benedict D. T. Daly MD

Authors
  1. Benedict D. T. Daly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benedict D. T. Daly MD .

Editor information

Editors and Affiliations

  1. Surgery, University of Chicago, Chicago, Illinois, USA

    Mark K. Ferguson

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Daly, B.D.T. (2014). Lobectomy After Induction Therapy for NSCLC in the Presence of Persistent N2 Disease. In: Ferguson, M. (eds) Difficult Decisions in Thoracic Surgery. Difficult Decisions in Surgery: An Evidence-Based Approach, vol 1. Springer, London. https://doi.org/10.1007/978-1-4471-6404-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-6404-3_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-6403-6

  • Online ISBN: 978-1-4471-6404-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation